The aim of this study is to assess treatment patterns, clinical outcomes, and patient characteristics among adults with metastatic castration-resistant prostate cancer (mCRPC) in the United States (US) real-world clinical practice. This study will be conducted using data extracted from the PRECISION (PRostatE Cancer dISease observatION) data platform.
Diagnosis of mCRPC between 01 January 2021 and 31 December 2025.
Male sex at index, where index is the date of initial mCRPC diagnosis.
Age 18 years at index.
None
Adult male patients with a confirmed mCRPC diagnosis in the US in the last 5 years who are included in the PRECISION data platform.
Cohort
Retrospective
Not listed
Number of Patients by Prior Therapies
Number of Patients by Number of Post-index Lines of Therapy (LOTs)
Number of Patients by Type of Therapy at Each LOT
Percentage of Patients Switching From One Type of Therapy to Another at Each LOT
Number of Patients by Patient Characteristics
Patient characteristics include race, geographical region, insurance status, marital status, type of treatment center, comorbidities, Gleason score, disease stage at diagnosis, and prostate-specific antigen (PSA) level.
Age
Progression-free Survival (PFS) From Index Date
PFS from index date: time from mCRPC diagnosis (index date) until progression or death from any cause.
PFS From Each LOT
PFS from each LOT, among those with that LOT: time from the date of initiation of the LOT until progression or death from any cause.
Click on the lead sponsor to view all of their trials.
